Chimerix to Report Second Quarter 2020 Financial Results and Provide an Operational Update on August 10, 2020
03 août 2020 08h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Appoints Allen Melemed, M.D. as Chief Medical Officer
22 juin 2020 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., June 22, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Present at H.C. Wainwright Virtual Fireside Chat Series
18 juin 2020 08h00 HE
|
Chimerix, Inc.
DURHAM, N.C., June 18, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Present at Jefferies Virtual Healthcare Conference
28 mai 2020 08h00 HE
|
Chimerix, Inc.
DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports First Quarter 2020 Financial Results and Provides Operational Update
07 mai 2020 07h00 HE
|
Chimerix, Inc.
DURHAM, N.C., May 07, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Announces Initiation of a Phase 2/3 Study of DSTAT in Acute Lung Injury for Patients with Severe COVID-19
29 avr. 2020 07h00 HE
|
Chimerix, Inc.
FDA Clearance to Proceed with Phase 2/3 Randomized, Double-Blind, Placebo Controlled Study Mechanisms of Action May Address Overactive Inflammatory Response, Including Underlying Causes of Blood...
Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
28 avr. 2020 16h30 HE
|
Chimerix, Inc.
DURHAM, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Present at Cowen and Company 40th Annual Health Care Conference
26 févr. 2020 08h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports Fourth Quarter and Year End 2019 Financial Results and Provides Operational Update
25 févr. 2020 07h00 HE
|
Chimerix, Inc.
- Successful DSTAT End of Phase 2 Meeting with FDA Confirms Phase 3 Readiness; First Patient Visit Expected mid-2020 in 1L AML - - Brincidofovir pre-NDA Meeting Scheduled with FDA, on Track for...
Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors
24 févr. 2020 08h00 HE
|
Chimerix, Inc.
DURHAM, N.C., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...